Ranking 7th! Nanjing Vcare Ranks among Top 20 Chinese R&D CRO Enterprises of 2026

2026-06-25

　　On June 25, the 2026 PDI Pharmaceutical R&D & Innovation Conference and the Launch Ceremony of Top 100 Pharmaceutical R&D Enterprises Ranking (the 11th PDI Conference) grandly opened in Chengdu, Sichuan Province, where the series of "2026 China Pharmaceutical R&D Strength Rankings" were unveiled. Leveraging outstanding innovation capacity and steadily growing R&D prowess, Nanjing Vcare PharmaTech Co.,Ltd. (Nanjing Vcare) has secured a spot on the "Top 20 Chinese Pharmaceutical CRO Enterprises" list for five consecutive years, jumping up to the 7th position this year.

 

　　Meanwhile, Hubei Tianshu Pharmaceutical Co., Ltd. Tianshu Pharmaceutical), the manufacturing base under Nanjing Vcare, has been listed on the "Top 20 Chinese Pharmaceutical CDMO Enterprises" ranking for two years running, further demonstrating the comprehensive competitive edge brought by Nanjing Vcare’s full industrial chain layout.

　　Top 10 Ranking for Five Straight Years with a Record-High Placement

　　Since its independent operation in 2021, Nanjing Vcare first made its debut on the Top 20 Chinese Pharmaceutical CRO Enterprises list in 2022 and has remained on this authoritative ranking ever since for five consecutive years. In 2026, the company climbed from 8th place last year to 7th, a testament to its consistent progress in technological innovation, service capability and industry influence.

　　The two major honors claimed by Nanjing Vcare and Tianshu Pharmaceutical fully reflect the high recognition and affirmation from industry leaders and peers of Nanjing Vcare’s strengths in R&D innovation, technical proficiency and growth potential.

　　Deep Cultivation of Full Industrial Chain, Continuous Leadership in Green Innovation

　　Adhering to an international vision centered on innovation and resource integration, Nanjing Vcare has long focused on full industrial chain and full life-cycle R&D and manufacturing services for chemical pharmaceuticals, while consistently boosting its CRO and CDMO service capabilities. Over the past year, the company has further expanded its core technological layout in synthetic biology and green manufacturing, and continuously upgraded core engineering technology platforms including biocatalysis enzymes and continuous flow chemistry to facilitate more efficient and eco-friendly pharmaceutical R&D and production.

　　Committed to advancing pharmaceutical innovation, Nanjing Vcare looks forward to cooperating with pharmaceutical companies and new drug R&D institutions worldwide. It delivers integrated, differentiated and customized full-chain services covering CDMO production and supply from pharmaceutical intermediates to APIs, as well as pharmaceutical CMC development, clinical C&D research and regulatory registration, empowering clients to thrive in all dimensions.

Next

Nanjing Vcare Concludes a Successful CPHI China 2026 in Shanghai: Expanding Global Footprint and Empowering Worldwide Clients through Technological Innovation